133487-66-8

Usage

Uses

Used in Organic Synthesis:
3-(2,2,3,3-tetrafluoropropoxy)benzaldehyde is used as a key intermediate in organic synthesis for the production of various pharmaceuticals, agrochemicals, and specialty chemicals. Its unique structure and reactivity make it a valuable building block in the synthesis of complex organic molecules.
Used in Organic Reactions:
3-(2,2,3,3-tetrafluoropropoxy)benzaldehyde is used as a reactant in various organic reactions, such as cross-coupling reactions, oxidation reactions, and reduction reactions. Its presence can enhance the reactivity and selectivity of these reactions, leading to the formation of desired products with improved yields and purity.
Used in Research and Development:
3-(2,2,3,3-tetrafluoropropoxy)benzaldehyde is used as a research compound in academic and industrial laboratories. It serves as a model compound for studying reaction mechanisms, exploring new synthetic routes, and developing innovative methodologies in organic chemistry.
It is important to handle this chemical with caution, as it may have hazardous properties and should only be used by trained professionals in a controlled laboratory environment.

Upstream product

• 76-37-9 2,2,3,3-tetrafluoropropanol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 679-87-8 1-iodo-1,1,3-trihydroperfluoropropane 
• 3132-99-8 m-bromobenzoic aldehyde 
• 786-31-2 p-toluenesulfonic acid-2,2,3,3-tetrafluoropropyl ester 

Downstream Products

• 467458-02-2 [2-(6-fluoro-1H-indol-3-yl)ethyl]({[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl})amine HCl salt 

Relevant academic research and scientific papers

Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer's disease

Beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of Alzheimer's disease (AD). As a result of complexity of AD, no molecule has been approved since 2002. Idalopirdine, a 5-HT6 receptors antagonist, did not show its effectiveness in clinical trial despite its evaluation as adjunct to cholinesterase inhibitors. Pleiotropic molecules, known as multitarget directed ligands (MTDLs) are currently developed to tackle the multifactorial origin of AD. In this context, we have developed a pleiotropic carbamate 7, that behaves as a covalent inhibitor of BuChE (IC50 = 0.97 μM). The latter will deliver after hydrolysis, compound 6, a potent 5-HT6 receptors antagonist (Ki = 11.4 nM) related to idalopirdine. In silico and in vitro evaluation proving our concept were performed completed with first in vivo results that demonstrate great promise in restoring working memory.

Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Synthesis of Fluorinated Alkyl Aryl Ethers by Palladium-Catalyzed C-O Cross-Coupling

Herein, we report a highly effective protocol for the cross-coupling of (hetero)aryl bromides with fluorinated alcohols using the commercially available precatalyst tBuBrettPhos Pd G3 and Cs2CO3 in toluene. This Pd-catalyzed coupling features a short reaction time, excellent functional group tolerance, and compatibility with electron-rich and-poor (hetero)arenes. The method provides access to 18F-labeled trifluoroethyl ethers by cross-coupling with [18F]trifluoroethanol.

Process for the Manufacture of Idalopirdine via Hydrogenation of an Imine

The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:

PROCESS FOR THE MANUFACTURE OF IDALOPIRDINE

Disclosed herein is a process for the preparation of idalopirdine and pharmaceutically acceptable salts thereof.